Literature DB >> 15319339

Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations.

Hannah M Jones1, J Brian Houston.   

Abstract

The substrate depletion method is a popular approach used for the measurement of in vitro intrinsic clearance (CL(int)). However, the incubation conditions used in these studies can vary, the consequences of which have not been systematically explored. Initial substrate depletion incubations using rat microsomes and hepatocytes were performed for eight benzodiazepines: alprazolam, clobazam, clonazepam, chlordiazepoxide, diazepam, flunitrazepam, midazolam, and triazolam. Subsequent predictions of in vivo CL(int) (ranging from 3 to 200 ml/min) and hepatic clearance (CL(H)) (ranging from 0.3 to 15 ml/min) demonstrated that the general predictive ability of this approach was similar to that of the traditional metabolite formation method. A more detailed study of the substrate depletion profiles and CL(int) estimates indicated that the concentration of enzyme used is of particular importance. The metabolism of triazolam, clonazepam, and diazepam was monoexponential at all cell densities using hepatocytes; however, with microsomes, biphasic depletion was apparent, particularly at higher microsomal protein concentrations (2-5 mg/ml). Enzyme activity studies indicated that enzyme loss was more pronounced in the microsomal system (ranged from 8 to 65% activity after a 1-h incubation) compared with the hepatocyte system (approximately 100% activity after a 1-h incubation). For clonazepam (a low clearance substrate), these biphasic profiles could be explained by loss of enzyme activity. To ensure accurate predictions of in vivo CL(int) and CL(H) when using the substrate depletion approach, based on the results obtained for this class of drugs, it is recommended that low enzyme concentrations and short incubation times are used whenever possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319339     DOI: 10.1124/dmd.104.000125

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  29 in total

1.  Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Authors:  David Hallifax; Joanne A Foster; J Brian Houston
Journal:  Pharm Res       Date:  2010-07-27       Impact factor: 4.200

2.  Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models.

Authors:  Sabine Pilari; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-27       Impact factor: 2.745

3.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.

Authors:  Daniel M Rotroff; Barbara A Wetmore; David J Dix; Stephen S Ferguson; Harvey J Clewell; Keith A Houck; Edward L Lecluyse; Melvin E Andersen; Richard S Judson; Cornelia M Smith; Mark A Sochaski; Robert J Kavlock; Frank Boellmann; Matthew T Martin; David M Reif; John F Wambaugh; Russell S Thomas
Journal:  Toxicol Sci       Date:  2010-07-16       Impact factor: 4.849

4.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes.

Authors:  Haiyan Li; Jin Sun; Xiaofan Sui; Zhongtian Yan; Yinghua Sun; Xiaohong Liu; Yongjun Wang; Zhonggui He
Journal:  AAPS J       Date:  2009-05-14       Impact factor: 4.009

Review 6.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

Review 7.  Addressing the challenges of low clearance in drug research.

Authors:  Li Di; R Scott Obach
Journal:  AAPS J       Date:  2015-01-08       Impact factor: 4.009

8.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

9.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

10.  Modelling and PBPK simulation in drug discovery.

Authors:  Hannah M Jones; Iain B Gardner; Kenny J Watson
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.